Drug profile · INN
interferon beta-1b
BETAFERON
interferon beta-1b (BETAFERON) is a interferon alpha/beta receptor agonist. Associated with Bayer Australia Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — interferon beta-1b
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
interferon beta-1b (BETAFERON) is a interferon alpha/beta receptor agonist. Associated with Bayer Australia Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interferon alpha/beta receptor agonist
Primary target: Interferon alpha/beta receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is interferon beta-1b?
interferon beta-1b (BETAFERON) is a interferon alpha/beta receptor agonist. Associated with Bayer Australia Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for interferon beta-1b?
BETAFERON is a marketed brand name for interferon beta-1b. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of interferon beta-1b?
interferon beta-1b has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.